annex i list of the names, pharmaceutical forms,...

1

Annex I

List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration and marketing authorisation holders in

the member states

2

Member State (in EEA)

Marketing authorisation holder

Product name Strength Pharmaceutical form Route of administration

Austria Forest Pharma B.V. Newtonlaan 115 3584 BH Utrecht The Netherlands

Colistin Forest - Trockenstechampullen mit Lösungsmittel

1000000 I.U. powder and solvent for suspension for injection, nebuliser solution

intramuscular use, intravenous use, inhalation use

Austria Profile Pharma Limited Chichester Business Park City Fields Way Tangmere, Chichester West Sussex PO20 2FT United Kingdom

Tadim 1 Million I.E. Pulver zur Herstellung einer Infusionslösung

1000000 I.U. powder for solution for infusion

intravenous use

Austria Xellia Pharmaceuticals ApS Dalslandsgade 11 DK-2300 Copenhagen S Denmark

Colistin Xellia 1 Million I.E. Pulver zur Herstellung einer Injektions-/Infusionslösung

1000000 I.U. powder for solution for injection/infusion

intravenous use

Austria Profile Pharma Limited Chichester Business Park City Fields Way Tangmere, Chichester West Sussex PO20 2FT United Kingdom

Tadim 1 Million I.E. Pulver zur Herstellung einer Lösung für einen Vernebler

1000000 I.U. powder for nebuliser solution

inhalation use

Austria PARI Pharma GmbH Moosstrasse 3 82319 Starnberg Germany

ColiFin 1 Mio. I.E. Pulver zur Herstellung einer Lösung für einen Vernebler


inhalation use

3




Austria PARI Pharma GmbH Moosstrasse 3 82319 Starnberg Germany

ColiFin 2 Mio. I.E. Pulver zur Herstellung einer Lösung für einen Vernebler


inhalation use

Belgium Forest Laboratories UK Ltd. Riverbridge House Anchor Boulevard Crossways Business Park Dartford Kent DA2 6SL United Kingdom

Colistineb 1000000 IE 1000000 I.U. powder for solution for injection/infusion

intravenous use, inhalation use

Belgium Forest Laboratories UK Ltd. Riverbridge House Anchor Boulevard Crossways Business Park Dartford Kent DA2 6SL United Kingdom

Colistineb 2000000 IE 2000000 I.U. powder for solution for injection/infusion


Bulgaria Alvogen IPCo.S.ar. I. 5 Rue Heienhaff Senningerberg L-1736 Luxembourg

Colistin Alvogen 1000000 I.U. powder for solution for injection/infusion

intravenous use

4




Bulgaria Alvogen IPCo.S.ar. I. 5 Rue Heienhaff Senningerberg L-1736 Luxembourg

Colistin Alvogen 2000000 I.U. powder for solution for injection/infusion

intravenous use

Croatia Altamedics d.o.o. Karlovačka cesta 24a, Zagreb 10020 Croatia

Colixin 1 milijun IU prašak za otopinu za injekciju

1000000 I.U. powder for solution for injection

intravenous use

Czech Republic

Forest Laboratories UK Limited Riverbridge House Anchor Boulevard Crossways Business Park Dartford Kent DA2 6SL United Kingdom

Colomycin injekce 1000000 IU

1000000 I.U. powder for solution for injection/infusion or nebuliser solution


Denmark Profile Pharma Limited Chichester Business Park City Fields Way Tangmere, Chichester West Sussex PO20 2FT United Kingdom

Promixin 1000000 I.U. nebuliser solution inhalation use

5




Denmark Profile Pharma Limited Chichester Business Park City Fields Way Tangmere, Chichester West Sussex PO20 2FT United Kingdom

Promixin 1000000 I.U. powder for solution for infusion

intravenous use

Denmark Xellia Pharmaceuticals ApS Dalslandsgade 11 DK-2300 Copenhagen S Denmark

Colistimethatnatrium "Xellia" 1000000 I.U. powder for solution for injection/infusion

intravenous use

France Sanofi-Aventis France 1-13 boulevard R. Rolland 75014 Paris France

COLIMYCINE 1 MUI, poudre et solvant pour inhalation par nébuliseur

1000000 I.U. powder and solvent for nebuliser solution

inhalation use

France Sanofi-Aventis France 1-13 boulevard R. Rolland 75014 Paris France

COLIMYCINE 1.000.000 U.I., poudre et solvant pour solution injectable

1000000 I.U. powder and solvent for solution for injection

intravenous use

6




France Profile Pharma Limited Chichester Business Park City Fields Way Tangmere, Chichester West Sussex PO20 2FT United Kingdom

TADIM 1 million d'unités internationales (UI) poudre pour solution pour inhalation par nébuliseur


inhalation use

Germany Forest Laboratories Nederland B.V. Newtonlaan 115 3584 BH Utrecht The Netherlands

Colistin CF 1000000 I.U. powder and solvent for nebuliser solution

inhalation use

Germany InfectoPharm Arzneimittel und Consilium GmbH Von-Humboldt-Straße 1 64646 Heppenheim Germany

Colistimethat-Natrium Infectopharm I.E. Pulver zur Herstellung einer Injektions- oder Infusionslösung


intravenous use

Germany InfectoPharm Arzneimittel und Consilium GmbH Von-Humboldt-Straße 1 64646 Heppenheim Germany

Colistimethat-Natrium Infectopharm I.E. Pulver zur Herstellung einer Injektions- oder Infusionslösung


intravenous use

7




Germany Profile Pharma Limited Bicentennial Building Southern Gate Chichester PO19 8EZ United Kingdom

Promixin 1 MI.E. Pulver zur Herstellung einer Lösung für einen Vernebler


inhalation use

Germany Profile Pharma Limited Bicentennial Building Southern Gate Chichester PO19 8EZ United Kingdom

Promixin 1 MI.E. Pulver zur Herstellung einer Lösung für einer Infusionslösung

1000000 I.U. powder for solution for infusion

intravenous use

Greece NORMA HELLAS AE 54 Menandrou str 10431 Athens Greece

COLISTIN/NORMA 1000000 I.U. powder for solution for injection

intramuscular use


COLISTIN/NORMA 1000000 I.U. powder and solvent for nebuliser solution

inhalation use


COLISTIN/NORMA 1000000 I.U. powder for solution for infusion

intravenous use

8





COLISTIN/NORMA 2000000 I.U. powder for solution for infusion

intravenous use

Greece ALLERTEC HELLAS AE 74 Karamanli str. 55134, Kalamaria, Thessaloniki Greece

TADIM 1000000 I.U. powder and solvent for nebuliser solution

inhalation use

Hungary Forest Laboratories UK Limited Riverbridge House Anchor Boulevard Crossways Business Park Dartford, Kent DA2 6SL United Kingdom

COLOMYCIN 1000000 I.U. powder for solution for injection/infusion, powder for nebuliser solution


Hungary Forest Laboratories UK Limited Riverbridge House Anchor Boulevard Crossways Business Park Dartford, Kent DA2 6SL United Kingdom

COLOMYCIN 2000000 I.U. powder for solution for injection/infusion, powder for nebuliser solution


9




Iceland Alvogen IPCo S.à.r.l., 5 Rue Heienhaff, L-1736 Senningerberg Luxembourg

Colistimethate Alvogen 1000000 I.U. powder for solution for injection or infusion

intravenous use

Iceland Alvogen IPCo S.à.r.l., 5 Rue Heienhaff, L-1736 Senningerberg Luxembourg

Colistimethate Alvogen 2000000 I.U. powder for solution for injection or infusion

intravenous use

Ireland Forest Laboratories UK Limited Riverbridge House Anchor Boulevard Crossways Business Park Dartford, Kent DA2 6SL United Kingdom

Colomycin Injection 1 million International Units. Powder for solution for injection, infusion or inhalation

1000000 I.U. powder for solution for injection, infusion or inhalation


Ireland Forest Laboratories UK Limited Riverbridge House Anchor Boulevard Crossways Business Park Dartford, Kent DA2 6SL United Kingdom

Colomycin Injection 2 million International Units. Powder for solution for injection, infusion or inhalation



10




Ireland Profile Pharma Limited Chichester Business Park City Fields Way Tangmere, Chichester West Sussex PO20 2FT United Kingdom

Promixin, 1 million International Units (IU), Powder for Nebuliser Solution


inhalation use

Italy UCB Pharma S.p.A.Via Gadames 5720151 - Milano (MI) Italy

COLIMICINA 1000000 I.U. powder and solvent for solution for injection

intramuscular use

Italy PARI Pharma GmbH Moosstrasse 3 82319 Starnberg Germany

COLFINAIR 1000000 I.U. powder for nebuliser solution

inhalation use

Italy PARI Pharma GmbH Moosstrasse 3 82319 Starnberg Germany

COLFINAIR 2000000 I.U. powder for nebuliser solution

Inhalation use

11




Italy Profile Pharma Limited Chichester Business Park City Fields Way Tangmere, Chichester West Sussex PO20 2FT United Kingdom

PROMIXIN 1000000 I.U. powder for nebuliser solution

Inhalation use

Luxembourg Profile Pharma Limited Chichester Business Park City Fields Way Tangmere, Chichester West Sussex PO20 2FT United Kingdom

Tadim 1000000 I.U. powder for nebuliser solution

inhalation use

Malta Forest Laboratories UK Limited Riverbridge House Anchor Boulevard Crossways Business Park Dartford, Kent DA2 6SL United Kingdom

Colomycin Injection 1million International Units powder for solution for injection, infusion or inhalation

1000000 I.U. powder for solution for injection/infusion/ inhalation


Norway Xellia Pharmaceuticals ApS Dalslandsgade 11 DK-2300 Copenhagen S Denmark

Colistimethate Xellia 1000000 I.U. powder for solution for infusion

intravenous use

12




Norway Profile Pharma Limited Chichester Business Park City Fields Way Tangmere, Chichester West Sussex PO20 2FT United Kingdom

Promixin 1000000 I.U. powder for nebuliser solution

nasal use

Norway Profile Pharma Limited Chichester Business Park City Fields Way Tangmere, Chichester West Sussex PO20 2FT United Kingdom

Promixin 1000000 I.U. powder for solution for infusion

intravenous use

Poland Tarchomińskie Zakłady Farmaceutyczne "Polfa" S.A. 2, A. Fleminga Str. 03-176 Warsaw Poland

Colistin TZF 1000000 I.U. powder for solution for injection, injection or inhalation


Poland Profile Pharma Limited Chichester Business Park City Fields Way Tangmere, Chichester West Sussex PO20 2FT United Kingdom


inhalation use

13




Portugal Generis Farmacêutica, S.A. Rua João de Deus 19 2700-487 Amadora Portugal

Colistina Generis 1000000 I.U. powder for solution for injection or for nebuliser solution


Portugal Pharmis Biofarmacêutica, Lda. Praceta do Farol, lote 101 Cascais 2750-341 Portugal

Colixin 2000000 I.U. powder for solution for injection or for nebuliser solution


Portugal Pharmis Biofarmacêutica, Lda. Praceta do Farol, lote 101 Cascais 2750-341 Portugal

Colixin 1000000 I.U. powder for solution for injection or for nebuliser solution


Portugal Profile Pharma Limited Chichester Business Park City Fields Way Tangmere, Chichester West Sussex PO20 2FT United Kingdom


inhalation use

Romania S.C. ANTIBIOTICE S.A., Str. Valea Lupului nr.1 707410 Iaşi România

COLISTINĂ ANTIBIOTICE 1000000 UI,


intravenous use

14




Romania Xellia Pharmaceuticals ApS Dalslandsgade 11 DK-2300 Copenhagen S Denmark

Colistimetat sodic Xellia 1 milion unităţi internaţionale (U.I.)


intravenous use

Slovak Republic

sanofi-aventis Slovakia s.r.o. Einsteinova 24 851 01 Bratislava Slovak Republic

Colimycine 1000000 I.U. powder for solution for injection

intravenous use, intramuscular use

Slovak Republic

Forest Laboratories UK Limited Riverbridge House Anchor Boulevard Crossways Business Park Dartford, Kent DA2 6SL United Kingdom

KOLOMYCÍN INJEKCIA 1 milión IU



Slovak Republic


KOLOMYCÍN INJEKCIA 2 milión IU



15




Spain GES GENÉRICOS ESPAÑOLES LABORATORIO, S.A. Cólquide, 6 - Portal 2, 1º-Oficina F 28230 Las Rozas (Madrid) Spain

Colistimetato de sodio GES 1 MUI polvo para solución inyectable/para inhalación por nebulizador

1000000 I.U. powder for solution for injection, powder for nebuliser solution


Spain Profile Pharma Limited Chichester Business Park City Fields Way Tangmere, Chichester West Sussex PO20 2FT United Kingdom

Promixin 1 millón de Unidades Internacionales (UI) polvo para solución para inhalación por nebulizador


inhalation use

Spain Pharmis Biofarmacêutica, Lda. Praceta do Farol, lote 101 Cascais 2750-341 Portugal

Colixin 1 MUI polvo para solución inyectable o para solución para inhalación por nebulizador

1000000 I.U. powder for solution for injection, powder for nebuliser solution


Sweden Profile Pharma Limited Bicentennial Building Southern Gate Chichester West Sussex PO19 8EZ United Kingdom

Tadim 1000000 I.U. powder for nebuliser solution

inhalation use

16




Sweden Profile Pharma Limited Bicentennial Building Southern Gate Chichester West Sussex PO19 8EZ United Kingdom

Tadim 1000000 I.U. powder for solution for infusion

intravenous use

Sweden Xellia Pharmaceuticals ApS Dalslandsgade 11 DK-2300 Copenhagen S Denmark

Colistin Xellia 1000000 I.U. powder for solution for injection/infusion

intravenous use

The Netherlands

Forest Pharma B.V. Newtonlaan 115 3584 BH Utrecht The Netherlands

Colistin, poeder voor verneveloplossing met oplosmiddel 1.000.000 IE


inhalation use

United Kingdom


Colomycin Injection 2 million international units powder for soln for inj, infusion or inhalation


intravenous use

17




United Kingdom


Colomycin Injection 1 million international units powder for soln for inj, infusion or inhalation



United Kingdom

Xellia Pharmaceuticals ApS Dalslandsgade 11 DK-2300 Copenhagen S Denmark

Colistimethate sodium 1 million international units powder for solution for injection or infusion


intravenous use

United Kingdom

Beacon Pharmaceuticals Limited, Tunbridge Wells, Kent TN1 1YG United Kingdom

Colistimethate sodium 1 million I.U. powder for solution for injection



United Kingdom

Profile Pharma Limited Chichester Business Park City Fields Way Tangmere, Chichester West Sussex PO20 2FT United Kingdom

Promixin 1 million international units (IU) powder for nebuliser solution


inhalation use

18




United Kingdom

Profile Pharma Limited Chichester Business Park City Fields Way Tangmere, Chichester West Sussex PO20 2FT United Kingdom

Promixin 1 million international units (IU) powder for solution for infusion


intramuscular use, intravenous use

United Kingdom

PARI Pharma GmbH Moosstrasse 3 82319 Starnberg Germany

Colifin 1 MIU powder for nebuliser solutions


inhalation use

United Kingdom

PARI Pharma GmbH Moosstrasse 3 82319 Starnberg Germany

Colifin 2 MIU powder for nebuliser solutions


inhalation use

19

Annex II

Scientific conclusions and grounds for maintenance of the marketing authorisations or the variation to the terms of the marketing

authorisations, as relevant

20

Scientific conclusions Overall summary of the scientific evaluation of polymyxin-based products (see Annex A and Annex I) The emergence of multi-drug resistant Gram-negative bacteria that cause nosocomial infections is a growing problem worldwide. Limited therapeutic options have led to an increased clinical use of colistin, a polymyxin antibiotic developed over 50 years ago and which has retained activity against a number of multi-drug resistant pathogens. This is possibly because of its limited parenteral use, due to the existence of safer, less neurotoxic and nephrotoxic therapeutic options. As a consequence, the existing preclinical and clinical pharmacokinetic (PK) and pharmacodynamic (PD) information is limited, the product information has not been significantly updated over the years and the dosage regimens in use today are not based upon robust PK/PD data. Indeed, recent clinical experience and the medical literature point to the urgent need to update the product information, in particular the indications, the dosage recommendations and the PK/PD information, as highlighted by recent reports of suboptimal efficacy and the emergence of colistin resistance, in particular when used as monotherapy. In addition, differences across the world in the expression of the strength and dose of colistin products may result in medication errors and put patients at risk. Polymyxins are currently listed among the critically important antimicrobials and in view of the importance of ensuring the availability of efficacious and safe antibiotics in order to efficiently respond to the threat posed by the spread of antimicrobial resistance, the European Commission initiated a procedure under Article 31 of Directive 2001/83/EC on 16 September 2013, requesting the CHMP to give its opinion on the benefit-risk of polymyxin-based products and on the need for regulatory measures. The CHMP decided that the medical need was greatest for high dose products for parenteral and inhalation use and that the scope of the review should be limited to these medicinal products. The scope of the procedure includes nationally-authorised medicinal products and a centrally-authorised medicinal product, Colobreathe (dry powder for inhalation), authorised in February 2012. In its assessment, the CHMP reviewed all available data, including submissions by marketing authorisation holders during the procedure and consulted the Pharmacokinetics Working Party and the Infectious Disease Working Party. Polymyxins are a group of naturally occurring antibiotics produced by the bacterium Paenibacillus polymyxa. Only polymyxin E (referred to as colistin) is approved for clinical use in the EU. Two forms of colistin are used clinically: colistin sulphate and its microbiologically inactive prodrug, colistimethate sodium (CMS). Colistin has a relatively high level of toxicity associated with parenteral administration and CMS was therefore developed for parenteral and inhalation use. CMS for parenteral use is indicated for the treatment of serious infections caused by Gram-negative pathogens and CMS for inhalation use is indicated for the management of chronic pulmonary infections due to P. aeruginosa in patients with cystic fibrosis. Having reviewed all available data, the CHMP considered that CMS and colistin represent a crucial therapeutic option in the armamentarium available to prescribers in the context of the treatment of infections caused by multi-drug resistant Gram-negative pathogens. A large number of PK/PD studies were reviewed together with data from clinical experience and the CHMP considered the available data to be sufficient to support revisions of the indication for both parenteral and inhalation use products, in line with clinical experience and current therapeutic guidelines. It was agreed that colistin can be used without age restrictions, but only for the treatment of serious infections. A key concern is to maintain the efficacy of colistin against multi-drug resistant pathogens and to avoid the selection of resistance arising from monotherapy and the CHMP therefore agreed recommendations for the co-administration of parenteral colistin with other antibiotics. The posology and method of administration section was also revised in its entirety, for all patient subpopulations, in order to define the optimal treatment regimens for achieving plasma concentrations above the critical minimal inhibitory concentrations. In particular, the CHMP considered that a loading dose should be administered, to ensure plasma concentrations above the minimum inhibitory concentration from the very first administration. However, data was extremely limited in certain patient populations and as a result, no firm recommendations could be made for patients with renal impairment, on renal replacement therapy or with hepatic impairment. Data was also particularly limited for paediatric patients. The CHMP reviewed the optimal way of expressing the strength and dose of polymyxin-containing products and was of the opinion that given the established use of international units (IU) in EU clinical practice and in the European and British Pharmacopoeia, the EU product information for CMS should

21

continue to be expressed in IU. However, the CHMP introduced a dose content conversion table between CMS expressed in IU, CMS expressed in mg and CBA expressed in mg, to raise awareness of the different ways of expressing the strength and dose and to help prescribers who obtain additional information from the literature. The CHMP also reviewed the data on adverse events observed with the use of colistin and agreed that the use of colistin for parenteral use is associated with nephrotoxicity and neurotoxicity but considered that these risks must be balanced against the risk of the underlying disease and the high mortality from the treated conditions and that they can be satisfactorily mitigated by statements in the SmPC. Finally, extensive revisions were made to reflect current pharmacokinetic and pharmacodynamic data, including an update of the EUCAST breakpoints and the list of susceptible species. Corresponding changes were made to the package leaflets. In conclusion, the CHMP is of the opinion that the benefit-risk of the polymyxin-based products included in the scope of this procedure remains positive, provided that changes, as applicable, are made to their product information as set out in Annex III to the opinion. Regarding the centrally-authorised product Colobreathe, the CHMP considered the product information to be up to date, with no need for revision. Therefore, for the medicinal products referred to in Annex I, the CHMP recommended the variation to the terms of the marketing authorisation, for which the relevant sections of the summary of product characteristics and package leaflet are set out in Annex III to the opinion. For Colobreathe, referred to in Annex A, the CHMP recommended the maintenance of the marketing authorisation, without any variations to the term of the marketing authorisation. Grounds for the maintenance and the variation to the terms of the marketing authorisation, as applicable Whereas

• the existing preclinical and clinical data and the product information including the indications, dosage recommendations and pharmacokinetic and pharmacodynamic information for polymyxin-based products in the EU are not up to date or based on robust data, as highlighted by recent reports of suboptimal efficacy and the emergence of colistin resistance,

• the CHMP carried out a benefit-risk evaluation of polymyxin-based products under Article 31 of Directive 2001/83/EC, reviewing all available data, including responses submitted by the marketing authorisation holders during the procedure and recommendations from the Pharmacokinetics and the Infectious Disease working parties,

• the CHMP considered that colistimethate sodium and colistin represent a crucial therapeutic option in the context of the treatment of infections caused by multi-drug resistant Gram-negative pathogens,

• the CHMP considered that the dose and strength of polymyxin-based products should continue to be expressed in international units,

• the CHMP considered the available data to be sufficient to support revisions of the indication for both parenteral use and inhalation use medicinal products, in line with clinical experience and current therapeutic guidelines

• the CHMP considered that the risks of nephrotoxicity and neurotoxicity observed with colistin for parenteral use should be balanced against the risk of the underlying disease and the high mortality from the treated conditions and that it can be satisfactorily mitigated by warnings and recommendations in the SmPC,

• the CHMP made extensive revisions to the SmPC to reflect current pharmacokinetic and pharmacodynamic data, including an update of the EUCAST breakpoints and the list of susceptible species,

The Committee, as a consequence, concluded that the benefit-risk balance of the polymyxin-based products included in the scope of this procedure remains positive under normal conditions of use, taking into account the agreed changes to the product information, as applicable.

22

Annex III

Amendments to relevant sections of the summary of product characteristics and the package leaflets

23

Changes agreed by the CHMP to the product information of CMS-containing products for injection or infusion Summary of Product Characteristics Section 4.1 Therapeutic indication Note: The wording of this section should be replaced with the following wording: [Product name] is indicated in adults and children including neonates for the treatment of serious infections due to selected aerobic Gram-negative pathogens in patients with limited treatment options (see sections 4.2, 4.4, 4.8 and 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents. Section 4.2 Posology and method of administration Note: The wording of this section should be replaced with the following wording: The dose to be administered and the treatment duration should take into account the severity of the infection as well as the clinical response. Therapeutic guidelines should be adhered to. The dose is expressed in international units (IU) of colistimethate sodium (CMS). A conversion table from CMS in IU to mg of CMS as well as to mg of colistin base activity (CBA) is included at the end of this section. Posology The following dose recommendations are made based on limited population-pharmacokinetic data in critically ill patients (see section 4.4): Adults and adolescents Maintenance dose 9MIU/day in 2-3 divided doses In patients who are critically ill, a loading dose of 9 MIU should be administered. The most appropriate time interval to the first maintenance dose has not been established. Modelling suggests that loading and maintenance doses of up to 12 MIU may be required in patients with good renal function in some cases. Clinical experience with such doses is however extremely limited, and safety has not been established. The loading dose applies to patients with normal and impaired renal functions including those on renal replacement therapy. Renal impairment Dose adjustments in renal impairment are necessary, but pharmacokinetic data available for patients with impaired renal function is very limited. The following dose adjustments are suggested as guidance. Dose reductions are recommended for patients with creatinine clearance < 50 ml/min: Twice daily dosing is recommended.

24

Creatinine clearance (ml/min)

Daily dose

< 50-30

5.5-7.5 MIU

<30-10

4.5-5.5 MIU

<10

3.5 MIU

MIU = million IU Haemodialysis and continuous haemo(dia)filtration Colistin appears to be dialyzable through conventional haemodialysis and continuous venovenous haemo(dia)filtration (CVVHF, CVVHDF). There are extremely limited data from population PK studies from very small numbers of patients on renal replacement therapy. Firm dose recommendations cannot be made. The following regimes could be considered. Haemodialysis No-HD days: 2.25 MIU/day (2.2-2.3 MIU/day). HD days: 3 MIU/day on haemodialysis days, to be given after the HD session. Twice daily dosing is recommended. CVVHF/ CVVHDF As in patients with normal renal function. Three times daily dosing is recommended. Hepatic impairment There are no data in patients with hepatic impairment. Caution is advised when administering colistimethate sodium in these patients. Older people No dose adjustments in older patients with normal renal function are considered necessary. Paediatric population The data supporting the dose regimen in paediatric patients are very limited. Renal maturity should be taken into consideration when selecting the dose. The dose should be based on lean body weight. Children ≤ 40kg 75.000-150.000 IU/kg/day divided into 3 doses. For children with a body weight above 40 kg, use of the dosing recommendation for adults should be considered. The use of doses >150.000 IU/kg/day has been reported in children with cystic fibrosis. There are no data regarding the use or magnitude of a loading dose in critically ill children. No dose recommendations have been established in children with impaired renal function. Note: The following intrathecal and intraventricular administration posology recommendations should be included in the SmPC as the current pharmaceutical formulation of all products included in this procedure is suitable for these routes of administration (based on the pH, absence of preservatives and antioxidant and volume for injection). Intrathecal and intraventricular administration Based on limited data, the following dose is recommended in adults: Intraventricular route

25

125.000 IU/day Intrathecally administered doses should not exceed those recommended for intraventricular use. No specific dosing recommendation can be made in children for intrathecal and intraventricular routes of administration. Method of administration [Product name] is administered intravenously as a slow infusion over 30 – 60 minutes. Colistimethate sodium undergoes hydrolysis to the active substance colistin in aqueous solution. For dose preparation, particularly where combination of multiple vials is needed, reconstitution of the required dose must be performed using strict aseptic technique (see section 6.6). Dose conversion table: In the EU, the dose of colistimethate sodium (CMS) must be prescribed and administered only as International Units (IU). The product label states the number of IU per vial. Confusion and medication errors have occurred because of the different expressions of dose in terms of potency. The dose is expressed in the US, and other parts of the world, as milligrams of colistin base activity (mg CBA). The following conversion table is prepared for information and the values must be considered nominal and approximate only. CMS conversion table

Potency ≈ mass of CMS (mg)* IU ≈ mg CBA

12.500 0.4 1 150.000 5 12 1.000.000 34 80 4.500.000 150 360 9.000.000 300 720

* Nominal potency of the drug substance = 12.500 IU/mg Section 4.3 Contraindications Note: If present, any contraindication in myasthenia gravis should be deleted, to be replaced with a warning in section 4.4, as indicated below. Section 4.4 Special warnings and precautions for use Note: The wording of this section should be revised for all SmPCs for products for intravenous administration of CMS/colistin to include the following warnings: Consideration should be given to co-administering intravenous colistimethate sodium with another antibacterial agent whenever this is possible, taking into account the remaining susceptibilities of the pathogen(s) under treatment. As the development of resistance to intravenous colistin has been reported in particular when it is used as a monotherapy, co- administration with other antibacterial should also be considered in order to prevent the emergence of resistance. There are limited clinical data on the efficacy and safety of intravenous colistimethate sodium. The recommended doses in all subpopulations are equally based on limited data (clinical and pharmacokinetic/ pharmacodynamics data). In particular there are limited safety data for the use of high doses (> 6MIU/day) and the use of a loading dose, and for special populations (patients with renal impairment and the paediatric population). Colistimethate sodium should only be used when other, more commonly prescribed antibiotics are not effective or not appropriate. Renal function monitoring should be performed at the start of treatment and regularly during treatment in all patients. The dose of colistimethate sodium should be adjusted according to creatinine clearance (see section 4.2). Patients who are hypovolaemic or those receiving other potentially nephrotoxic drugs are at increased risk of nephrotoxicity from colistin (see sections 4.5 and 4.8).

26

Nephrotoxicity has been reported to be associated with cumulative dose and treatment duration in some studies. The benefit of prolonged treatment duration should be balanced against the potentially increased risk of renal toxicity. Caution is advised when administering colistimethate sodium to infants < 1 year of age as renal function is not fully mature in this age group. Further, the effect of immature renal and metabolic function on the conversion of colistimethate sodium to colistin is not known. In case of an allergic reaction, treatment with colistimethate sodium must be discontinued and appropriate measures implemented. High serum concentrations of colistimethate sodium, which may be associated with overdosage or failure to reduce the dosage in patients with renal impairment, have been reported to lead to neurotoxic effects such as facial paraesthesia, muscle weakness, vertigo, slurred speech, vasomotor instability, visual disturbances, confusion, psychosis and apnoea. Monitoring should be performed for perioral paraesthesia and paraesthesia in the extremities, which are signs of overdose (see section 4.9). Colistimethate sodium is known to reduce the presynaptic release of acetyl-choline at the neuro-muscular junction and should be used in patients with myasthenia gravis with the greatest caution and only if clearly needed. Respiratory arrest has been reported following intramuscular administration of colistimethate sodium. Impaired renal function increases the possibility of apnoea and neuromuscular blockade following administration of colistimethate sodium. Colistimethate sodium should be used with extreme caution in patients with porphyria. Antibiotic-associated colitis and pseudomembranous colitis have been reported with nearly all anti-bacterial agents and may occur with colistimethate sodium. They may range from mild to life-threatening in severity. It is important to consider this diagnosis in patients who develop diarrhoea during or after the use of colistimethate sodium (see section 4.8). Discontinuation of therapy and the administration of specific treatment for Clostridium difficile should be considered. Medicinal products that inhibit peristalsis should not be given. Note: If intrathecal administration is included in the SmPC of your product, the following should also be included: Intravenous colistimethate sodium does not cross the blood brain barrier to a clinically relevant extent. The use of intrathecal or intraventricular administration of colistimethate sodium in the treatment of meningitis was not systematically investigated in clinical trials and is supported by case reports only. Data supporting the posology are very limited. The most commonly observed adverse effect of CMS administration was aseptic meningitis (see section 4.8). Section 4.5 Interaction with other medicinal products and other forms of interaction Note: The wording of this section should be revised for all SmPCs for products for intravenous administration of CMS/colistin to include the following statements: Concomitant use of intravenous colistimethate sodium with other medications that are potentially nephrotoxic or neurotoxic should be undertaken with great caution. Caution should be taken with concomitant use with other formulations of colistimethate sodium as there is little experience and there is a possibility of summative toxicity. No in vivo interaction studies have been performed. The mechanism of conversion of colistimethate sodium to the active substance, colistin, is not characterised. The mechanism of colistin clearance, including renal handling, is equally unknown. Colistimethate sodium or colistin did not induce the activity of any P 450 (CYP) enzyme tested (CYP1A2, 2B6, 2C8, 2C9, 2C19 and 3A4/5) in in vitro studies in human hepatocytes. The potential for drug-drug interactions should be borne in mind when [Product name] is co-administered with drugs known to inhibit or induce drug metabolising enzymes or drugs known to be substrates for renal carrier mechanisms.

27

Due to the effects of colistin on the release of acetylcholine, non-depolarising muscle relaxants should be used with caution in patients receiving colistimethate sodium as their effects could be prolonged (see section 4.4). Co-treatment with colistimethate sodium and macrolides such as azithromycin and clarithromycin, or fluoroquinolones such as norfloxacin and ciprofloxacin should be undertaken with caution in patients with myasthenia gravis (see section 4.4). Section 5.1 Pharmacodynamic properties Note: The wording of this section should be revised for all SmPCs for products for intravenous administration of CMS/colistin to include the following statements: Pharmacotherapeutic group: antibacterials for systemic use, other antibacterials, polymyxins. ATC Code: J01XB01 Mechanism of action Colistin is a cyclic polypeptide antibacterial agent belonging to the polymyxin group. Polymyxins work by damaging the cell membrane and the resulting physiological effects are lethal to the bacterium. Polymyxins are selective for aerobic Gram-negative bacteria that have a hydrophobic outer membrane. Resistance Resistant bacteria are characterised by modification of the phosphate groups of lipopolysaccharide, which become substituted with ethanolamine or aminoarabinose. Naturally resistant Gram-negative bacteria, such as Proteus mirabilis and Burkholderia cepacia, show complete substitution of their lipid phosphate by ethanolamine or aminoarabinose. Cross resistance between colistin (polymyxin E) and polymyxin B is expected. Since the mechanism of action of the polymyxins is different from that of other antibacterial agents, resistance to colistin and polymyxin by the above mechanism alone would not be expected to result in resistance to other drug classes. PK/PD relationship Polymyxins have been reported to have a concentration-dependent bactericidal effect on susceptible bacteria. fAUC/ MIC is considered to be correlated with clinical efficacy. EUCAST Breakpoints Susceptible (S) Resistant (R) a

Acinetobacter S≤2 R>2 mg/L

Enterobacteriaceae S≤2 R>2 mg/L

Pseudomonas spp S≤4 R>4 mg/L a Breakpoints apply to dosage of 2-3 MIU x 3. A loading dose (9 MIU) may be needed. Susceptibility The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent, in at least some types of infections, is questionable. Commonly susceptible species Acinetobacter baumannii Haemophilus influenzae Klebsiella spp Pseudomonas aeruginosa Species for which acquired resistance may be a problem Stenotrophomonas maltophilia Achromobacter xylosoxidans (formerly Alcaligenes xylosoxidans) Inherently resistant organisms

28

Burkholderia cepacia and related species Proteus spp Providencia spp Serratia spp Section 5.2 Pharmacokinetic properties Note: The wording of this section should be revised for all SmPCs for products for intravenous administration of CMS/colistin to include the following statements: The information on the pharmacokinetics of colistimethate sodium (CMS) and colistin is limited. There are indications that pharmacokinetics in critically ill patients differ from those in patients with less severe physiological derangement and from those in healthy volunteers. The following data are based on studies using HPLC to determine CMS/colistin plasma concentrations. After infusion of colistimethate sodium the inactive pro-drug is converted to the active colistin. Peak plasma concentrations of colistin have been shown to occur with a delay of up to 7 hours after administration of colistimethate sodium in critically ill patients. Distribution The volume of distribution of colistin in healthy subjects is low and corresponds approximately to extracellular fluid (ECF). The volume of distribution is relevantly enlarged in critically ill subjects. Protein binding is moderate and decreases at higher concentrations. In the absence of meningeal inflammation, penetration into the cerebrospinal fluid (CSF) is minimal, but increases in the presence of meningeal inflammation. Both CMS and colistin display linear PK in the clinically relevant dose range. Elimination It is estimated that approximately 30% of colistimethate sodium is converted to colistin in healthy subjects, its clearance is dependent on creatinine clearance and as renal function decreases, a greater portion of CMS is converted to colistin. In patients with very poor renal function (creatinine clearance <30 ml/min), the extent of conversion could be as high as 60 to 70%. CMS is eliminated predominantly by the kidneys via glomerular filtration. In healthy subjects, 60% to 70% of CMS is excreted unchanged in the urine within 24 hours. The elimination of the active colistin is incompletely characterised. Colistin undergoes extensive renal tubular reabsorption and may either be cleared non-renally or undergo renal metabolism with the potential for renal accumulation. Colistin clearance is decreased in renal impairment, possibly due to increased conversion of CMS. Half-life of colistin in healthy subjects and those with cystic fibrosis is reported to be around 3h and 4h, respectively, with a total clearance of around 3L/h. In critically ill patients, half-life has been reported to be prolonged to around 9-18h. Package Leaflet 1. What [Product name] is and what it is used for Note: The existing package leaflet shall be amended (insertion, replacement or deletion of the text as appropriate) to reflect the wording below: [Product name] is given by injection to treat some types of serious infections caused by certain bacteria. [Product name] is used when other antibiotics are not suitable. 2. What you need to know before you <take> <use> [Product name] Note: The existing package leaflet shall be amended (insertion, replacement or deletion of the text as appropriate) to reflect the wording below. If present, any contraindication in myasthenia gravis should be deleted, to be replaced with a warning, as indicated below. Do not <take><use> [Product name] - If you are allergic (hypersensitive) to colistimethate sodium, colistin or to other polymyxins.

29

Warnings and precautions Talk to your doctor, pharmacist or nurse before using [Product name] - If you have or have had kidney problems. - If you suffer from myasthenia gravis - If you suffer from porphyria In premature and new-born babies, special care should be taken when using [Product name] as the kidneys are not yet fully developed. Other medicines and [Product name] - medicines which can affect how your kidneys function. Taking such medicines at the same time as [Product name] can increase the risk of damage to the kidneys - medicines which can affect your nervous system. Taking such medicines at the same time as [Product name] can increase the risk of side effects in your nervous system - medicines called muscle relaxants, often used during general anaesthesia. [Product name] can increase the effects of these medicines. If you have a general anaesthetic, let your anaesthetist know that you are having [Product name] If you suffer from myasthenia gravis and are also taking other antibiotics called macrolides (such as azithromycin, clarithromycin or erythromycin) or antibiotics called fluoroquinolones (such as ofloxacin, norfloxacin and ciprofloxacin), taking [Product name] further increases the risk of muscle weakness and breathing difficulties. Having [Product name] as an infusion at the same time as receiving [Product name] as an inhalation can increase your risk of side effects. 3. How to <take><use> [Product name] Note: The existing package leaflet shall be amended (insertion, replacement or deletion of the text as appropriate) to reflect the wording below. A tabulated presentation of the posology could be considered acceptable. [Product name] is given to you by your doctor as an infusion into a vein over 30 – 60 minutes. The usual daily dose in adults is 9 million units, divided into two or three doses. If you are quite unwell, you will be given a higher dose of 9 million units once at the start of treatment. In some cases, your doctor may decide to give a higher daily dose of up to 12 million units. The usual daily dose in children weighing up to 40 kg is 75.000 to 150.000 units per kilogram body weight, divided into three doses. Higher doses have occasionally been given in cystic fibrosis. Children and adults with kidney problems, including those on dialysis, are usually given lower doses. Your doctor will monitor your kidney function regularly while you receive [Product name].

30

Changes agreed by the CHMP to the Product Information of CMS-containing products for solution for inhalation or nebulisation Summary of Product Characteristics Note: The wording of this section should be replaced with the following wording: Section 4.1 Therapeutic indications [Product name] is indicated for the management in adult and paediatric of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (see section 5.1). Consideration should be given to official guidance on the appropriate use of antibacterial agents. Section 4.2 Posology and method of administration Note: The wording of this section should be replaced with the following wording: It is recommended that colistimethate sodium (CMS) should be administered under the supervision of physicians with appropriate experience in its use. Posology The dosage can be adjusted depending on the severity of the condition and clinical response. Recommended dose range: Administration via inhalation Adults, adolescents and children ≥ 2 years 1-2 MIU two to three times per day (max 6 MIU/day) Children < 2 years 0.5-1 MIU twice daily (max 2 MIU/ day) Relevant clinical guidance on treatment regimens, including duration of treatment, periodicity and co-administration of other antibacterial agents should be adhered to. Older people Dose adjustment is not considered necessary Renal impairment Dose adjustment is not considered necessary, however caution is advised in patients with renal impairment (see sections 4.4 and 5.2). Hepatic impairment Dose adjustment is not considered necessary Method of administration For inhalation use. [Information on suitable nebuliser(s) and output characteristics may be included] Colistimethate sodium undergoes hydrolysis to the active substance colistin in aqueous solution. For special precautions for disposal and handling of reconstituted solutions, see section 6.6. If other treatments are being taken, they should be taken in the order recommended by the physician. Dose conversion table: In the EU, the dose of colistimethate sodium (CMS) must be prescribed and administered only as International Units (IU). The product label states the number of IU per vial.

31

Confusion and medication errors have occurred because of the different expressions of dose in terms of potency. The dose is expressed in the US, and other parts of the world, as milligrams of colistin base activity (mg CBA). The following conversion table is prepared for information and the values must be considered nominal and approximate only. CMS conversion table

Potency ≈ mass of CMS (mg)* IU ≈ mg CBA

12.500 0.4 1 150.000 5 12 1.000.000 34 80 4.500.000 150 360 9.000.000 300 720

* Nominal potency of the drug substance = 12.500 IU/mg Package Leaflet 1. What [Product name] is and what it is used for Note: The existing package leaflet shall be amended (insertion, replacement or deletion of the text as appropriate) to reflect the wording below: [Product name] is given as an inhalation to treat chronic chest infections in patients with cystic fibrosis. [Product name] is used when these infections are cause by specific bacteria called Pseudomonas aeruginosa. 2. What you need to know before you <take> <use> [Product name] Note: The existing package leaflet shall be amended (insertion, replacement or deletion of the text as appropriate) to reflect the wording below. If present, any contraindication in myasthenia gravis should be deleted, to be replaced with a warning, as indicated below. Do not <take><use> [Product name]

- If you are allergic (hypersensitive) to colistimethate sodium, colistin or to other polymyxins. Warnings and precautions Talk to your doctor, pharmacist or nurse before using [Product name] - If you have or have had kidney problems. - If you suffer from myasthenia gravis - If you suffer from porphyria - If you suffer from asthma. In premature and new-born babies, special care should be taken when using [Product name] as the kidneys are not yet fully developed. Other medicines and [Product name] - medicines which can affect how your kidneys function. Taking such medicines at the same time as [Product name] can increase the risk of damage to the kidneys. - medicines which can affect your nervous system. Taking such medicines at the same time as [Product name] can increase the risk of side effects in your nervous system - medicines called muscle relaxants, often used during general anaesthesia. [Product name] can increase the effects of these medicines. If you have a general anaesthetic, let your anaesthetist know that you are having [Product name] If you suffer from myasthenia gravis and are also taking other antibiotics called macrolides (such as azithromycin, clarithromycin or erythromycin) or antibiotics called fluoroquinolones (such as ofloxacin, norfloxacin and ciprofloxacin), taking [Product name] further increases the risk of muscle weakness and breathing difficulties.

32

Having [Product name] as an infusion at the same time as receiving [Product name] as an inhalation can increase your risk of side effects. 3. How to <take><use> [Product name] Note: The existing package leaflet shall be amended (insertion, replacement or deletion of the text as appropriate) to reflect the wording below. A tabulated presentation of the posology could be considered acceptable. The usual dose for adults, adolescents and children aged 2 years or older is 1-2 million units two to three times per day (maximum 6 million units per day). The usual dose for children less than 2 years old is 0.5-1 million units twice daily (maximum 2 million units per day). Your doctor may decide to adjust the dose depending on your circumstances. If you also take other inhaled medicines, your doctor will tell you which order to taken them in.

annex i list of the names, pharmaceutical forms,...

Documents